All In Biotech

Drug Trial Radar · NCT00418886

Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients

A Phase III, Randomized, Double-blinded, Parallel Group, Multi-centre Study to Assess the Efficacy and Safety of ZD6474 (ZACTIMA™) in Combination With Pemetrexed (Alimta®) Versus Pemetrexed Alone in Patients With Locally-Advanced or Metastatic NSCLC

Last checked: Nov 20, 2026Latest source record: Dec 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 698 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

698

Actual

Start

Jan 2007

Primary completion

Sep 2008

Study completion Feb 14, 2023

Sponsor

Lead sponsor
Genzyme, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Jan 5, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Non-small cell lung cancer (NSCLC) can be treated with drugs that kill tumour cells, stop them from dividing, or stop the growth of the blood supply that cancers need to grow and spread. Clinical research has shown that drugs that inhibit vascular endothelial growth factor receptor (VEGFR) or epidermal growth factor receptor (EGFR) signalling can increase overall survival in patients with advanced non-small cell lung cancer (NSCLC). Preclinical studies have shown that vandetanib (ZD6474) is an inhibitor of both VEGFR and EGFR signalling. Giving vandetanib may therefore inhibit the growth of cancer cells by blocking their blood supply and by stopping them from dividing. This lung cancer study is to investigate if adding vandetanib to Alimta (pemetrexed) is more effective than Alimta (pemetrexed) alone.

Conditions

  • Non Small Cell Lung Cancer
  • Lung Cancer

Interventions

  • VandetanibDrug

    oral once daily tablet

  • PemetrexedDrug

    intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS) in the Overall PopulationTime frame: RECIST tumour assessments carried out every 6 weeks (+/- 3 days) from randomization until objective progression
  2. Progression-Free Survival in the Female PopulationTime frame: RECIST tumour assessments carried out every 6 weeks (+/- 3 days) from randomization until objective progression

Locations

110 sites in 21 countries. Site status is shown where the registry gives one.

  • Research Site

    Casa Grande, Arizona

  • Research Site

    Chandler, Arizona

  • Research Site

    Farmington, Connecticut

  • Research Site

    Stamford, Connecticut

  • Research Site

    Washington D.C., District of Columbia

  • Research Site

    Orlando, Florida

  • Research Site

    Gainesville, Georgia

  • Research Site

    Skokie, Illinois

  • Research Site

    Sioux City, Iowa

  • Research Site

    Mount Sterling, Kentucky

  • Research Site

    Portland, Maine

  • Research Site

    Baltimore, Maryland

  • Research Site

    Rockville, Maryland

  • Research Site

    Boston, Massachusetts

  • Research Site

    St Louis, Missouri

  • Research Site

    Mineola, New York

  • Research Site

    Rochester, New York

  • Research Site

    Winston-Salem, North Carolina

  • Research Site

    Cincinnati, Ohio

  • Research Site

    Middletown, Ohio

  • Research Site

    Hilton Head Island, South Carolina

  • Research Site

    Austin, Texas

  • Research Site

    Salt Lake City, Utah

  • Research Site

    Avellaneda, Argentina

  • Research Site

    Buenos Aires, Argentina

  • Research Site

    Ciudad de Buenos Aires, Argentina

  • Research Site

    Córdoba, Argentina

  • Research Site

    La Plata, Argentina

  • Research Site

    Ramos Mejía, Argentina

  • Research Site

    Salta, Argentina

  • Research Site

    Santa Fe, Argentina

  • Research Site

    Chermside, Australia

  • Research Site

    Fitzroy, Australia

  • Research Site

    Footscray, Australia

  • Research Site

    Heidelberg, Australia

  • Research Site

    Randwick, Australia

  • Research Site

    St Leonards, Australia

  • Research Site

    Wodonga, Australia

  • Research Site

    Brussels (Woluwé-St-Lambert), Belgium

  • Research Site

    Leuven, Belgium

Showing 40 of 110 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.